CRDL (Cardiol Therapeutics Inc. Class A Common Shares) Stock Analysis - Analyst Ratings

Cardiol Therapeutics Inc. Class A Common Shares (CRDL) is a publicly traded Healthcare sector company. As of May 21, 2026, CRDL trades at $1.30 with a market cap of $147.55M and a P/E ratio of 0.00. CRDL moved +3.17% today. Year to date, CRDL is +30.00%; over the trailing twelve months it is +16.07%. Its 52-week range spans $0.77 to $2.24. Analyst consensus is buy with an average price target of $8.50. Rallies surfaces CRDL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate CRDL?

2 analysts cover CRDL: 0 strong buy, 2 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $8.50.

CRDL Key Metrics

Key financial metrics for CRDL
MetricValue
Price$1.30
Market Cap$147.55M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$2.24
52-Week Low$0.77
Volume0
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

CRDL Analyst Consensus

2 analysts cover CRDL: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.50.

Latest CRDL News

Common questions about CRDL

What do analysts rate CRDL?
2 analysts cover CRDL: 0 strong buy, 2 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $8.50.
Does Rallies show CRDL price targets?
Yes. Rallies tracks CRDL analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is CRDL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CRDL. It does not provide personalized investment advice.
CRDL

CRDL